Similar articles

• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Nicholls SJ, et al. JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649. JAMA. 2011. PMID: 22089718 Clinical Trial.
• Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?

  Duriez P. Duriez P. Curr Atheroscler Rep. 2008 Jun;10(3):177-9. doi: 10.1007/s11883-008-0027-x. Curr Atheroscler Rep. 2008. PMID: 18489843 No abstract available.
• Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

  Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Hovingh GK, et al. Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2. Lancet. 2015. PMID: 26047975 Clinical Trial.
• Anacetrapib: a new weapon against dyslipidemia.

  Aperis G, Paliouras C, Tsampikaki E, Papakonstantinou N, Alivanis P. Aperis G, et al. Curr Clin Pharmacol. 2011 Nov;6(4):227-35. doi: 10.2174/157488411798375949. Curr Clin Pharmacol. 2011. PMID: 22082322 Review.
• The treatment of dyslipidemia--what's left in the pipeline?

  Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M. Rau O, et al. ChemMedChem. 2008 Feb;3(2):206-21. doi: 10.1002/cmdc.200700165. ChemMedChem. 2008. PMID: 17963209 Review.